How were Histogenics' earnings last quarter?

Histogenics Corp (NASDAQ:HSGX) posted its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.10.

What other stocks do shareholders of Histogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Histogenics investors own include Interpace Biosciences (IDXG) , Novavax (NVAX) , Verastem (VSTM) , Progenics Pharmaceuticals (PGNX) , SCYNEXIS (SCYX) , Magnegas Applied Tchnlgy Sltns (MNGA) , Ocular Therapeutix (OCUL) , Trevena (TRVN) , OPKO Health (OPK) and Synergy Pharmaceuticals (SGYP) .

When did Histogenics IPO?

Histogenics (HSGX) raised $60 million in an initial public offering (IPO) on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

NASDAQ:HSGX

Histogenics (HSGX) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free HSGX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.27
▼
$1.37
50-Day Range: $0.16
▼
$3.07
52-Week Range: $0.08
▼
$1.43

Volume: 6.51 million shs
Average Volume: 9.06 million shs
Market Capitalization: $124.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get Histogenics alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Histogenics Stock (NASDAQ:HSGX)

Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

HSGX Stock News Headlines

April 8, 2023 | thetimes.co.uk

Feargal Sharkey: Desperate revival of failed policies doesn’t add up

September 21, 2022 | streetinsider.com

Aspect Biosystems Appoints Three New Board Members - StreetInsider.com

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

September 21, 2022 | businesswire.com

Aspect Biosystems Appoints Three New Board Members - Business Wire

August 24, 2022 | investing.com

Are Ocugen Or Amarin Good Stocks To Buy? - Investing.com

August 5, 2022 | stockhouse.com

2022-08-05 | NDAQ:OCGN | Press Release | Ocugen, Inc. - Stockhouse

June 23, 2022 | gurufocus.com

Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition - GuruFocus.com

May 25, 2022 | uk.investing.com

Ocugen Diversifies Its Pipeline With New Cell Therapy Platform By Benzinga - Investing.com UK

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

May 25, 2022 | globenewswire.com

Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition - GlobeNewswire

May 24, 2022 | streetinsider.com

Ocugen (OCGN) Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition - StreetInsider.com

April 18, 2022 | streetinsider.com

Form DEF 14A Aurinia Pharmaceuticals For: Apr 18 - StreetInsider.com

March 8, 2022 | investorplace.com

Ocugen Is Two Strikes in With a Third in the Books - InvestorPlace

October 26, 2021 | news.yahoo.com

CN.ORTH: New Blood on The Board - Yahoo Finance

September 21, 2021 | prnewswire.com

Global Cell Therapy Market Outlook, Patent & Clinical Trials Report 2021-2028: Clinical & Commercial Insight On 32 Cell Therapies Available & Insight on 1600+ Cell Therapies in Clinical Trials - PRNewswire

September 8, 2021 | streetinsider.com

Form 8-K APPLIED GENETIC TECHNOLO For: Sep 08 - StreetInsider.com

See More Headlines

Receive HSGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Histogenics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/09/2018
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical Appliances & Supplies
Sub-Industry: N/A
Current Symbol: NASDAQ:HSGX
CUSIP: N/A
CIK: 1372299
Web: www.histogenics.com
Phone: 781-547-7900
Fax: N/A
Employees: 49
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.79)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,640,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -34.96%
Return on Assets: 18.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.05
Quick Ratio: 4.05

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.01) per share
Price / Book: -132.00

Miscellaneous

Outstanding Shares: 94,599,000
Free Float: N/A
Market Cap: $124.87 million
Optionable: Not Optionable
Beta: 3.10

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Adam D. Gridley (Age 47)
Interim Pres, CEO Treasurer, Sec., Consultant & Director
Mr. Jonathan I. Lieber (Age 49)
Interim Chief Financial Officer
Mr. Stephen R. Kennedy (Age 62)
Consultant

Key Competitors

View All Competitors

HSGX Stock Analysis - Frequently Asked Questions

How were Histogenics' earnings last quarter?: Histogenics Corp (NASDAQ:HSGX) posted its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.10.
What other stocks do shareholders of Histogenics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Histogenics investors own include Interpace Biosciences (IDXG), Novavax (NVAX), Verastem (VSTM), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Magnegas Applied Tchnlgy Sltns (MNGA), Ocular Therapeutix (OCUL), Trevena (TRVN), OPKO Health (OPK) and Synergy Pharmaceuticals (SGYP).
When did Histogenics IPO?: Histogenics (HSGX) raised $60 million in an initial public offering (IPO) on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

This page (NASDAQ:HSGX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Histogenics (HSGX) Stock Price, News & Analysis

About Histogenics Stock (NASDAQ:HSGX)

HSGX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

HSGX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info